EB
Emergent BioSolutions Inc.
EBS · NYSE
$5.88 +3.52% (+$0.20)
1M +29.01%
Market Cap $303.4M
P/E Ratio -
Div. Yield -
ROE 35.91%
Bulios Fair Price
$3.23
45.1% downside
Current Price
$5.88
Undervalued Fair Value Overvalued
According to Bulios Fair Price, EBS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
100 /100
Cheap P/B 0.89x
P/FCF 3.53x
P/S 0.39x
Growth
0 /100
Declining Book val. growth 27.79%
Rev. growth 12.72%
FCF growth N/A
Profitability
41 /100
Moderate Net margin 22.96%
Op. margin 7.06%
FCF margin 11.15%
Quality
9 /100
Poor ROE 35.91%
ROA 15.83%
Asset turnover 0.69x
Debt
36 /100
Moderate Current ratio 5.42x
Int. coverage -1.87x
Debt/Equity 1.70x
Stability
25 /100
Unstable Rev. volatility 14.98%
EPS volatility 205.16%
Profitable years 1
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about EBS
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Joseph C. Papa Jr.
Employees
900
Headquarters
Gaithersburg
Upcoming events
04 NOV
Earnings
Upcoming earnings report